Status:
RECRUITING
CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry
Lead Sponsor:
Universitätsklinikum Hamburg-Eppendorf
Collaborating Sponsors:
Montreal Heart Institute
University Hospital, Bordeaux
Conditions:
Mitral Regurgitation
Eligibility:
All Genders
18+ years
Brief Summary
This multinational, investigator-initiated, retrospective study aims to investigate outcomes of patients, who underwent transcatheter mitral valve implantation (TMVI), in comparison to those screened ...
Eligibility Criteria
Inclusion
- clinically significant mitral insufficiency
- patient underwent screening for TMVI
- echocardiography data at baseline (and after TMVI, E2E and surgery)
- follow-up of at least 30 days
Exclusion
- \- age under 18 years
Key Trial Info
Start Date :
November 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT04688190
Start Date
November 1 2020
End Date
December 31 2030
Last Update
May 17 2022
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center, Los Angeles
Los Angeles, California, United States, 90048
2
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
3
Houston Methodist Hospital
Houston, Texas, United States, 77030
4
St Vincent's Hospital
Sydney, Australia